Trifecta Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Trifecta Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$915	Buy	+27	New	+$899	﹤0.01%	377

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Trifecta Capital Advisors's TEVA Position: Q2 2026 in Review

Trifecta Capital Advisors opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 27 shares worth $915. The stake represents ﹤0.01% of the portfolio and ranks #377 among its holdings.

672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Trifecta Capital Advisors held 27 shares of Teva Pharmaceuticals worth $915 as of Q2 2026.
Teva Pharmaceuticals was a new Trifecta Capital Advisors position in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #377 holding.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.